Grifols (GRFS) Expected to Announce Quarterly Earnings on Wednesday

Grifols (NASDAQ:GRFS) is projected to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.29 per share and revenue of $1.9551 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 AM ET.

Grifols Stock Performance

Shares of GRFS opened at $9.40 on Monday. The company has a current ratio of 2.48, a quick ratio of 0.93 and a debt-to-equity ratio of 1.20. The firm has a 50-day moving average price of $9.21 and a 200 day moving average price of $9.39. Grifols has a 52-week low of $6.19 and a 52-week high of $11.14.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GRFS. Zacks Research upgraded shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a research note on Thursday, January 22nd. JPMorgan Chase & Co. lowered their price target on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research report on Monday, December 8th. Finally, Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Four investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $10.00.

Institutional Investors Weigh In On Grifols

Several hedge funds have recently modified their holdings of GRFS. BNP Paribas Financial Markets boosted its stake in Grifols by 69.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 193,173 shares of the biotechnology company’s stock worth $1,746,000 after purchasing an additional 79,099 shares during the period. Jane Street Group LLC raised its stake in Grifols by 1,045.8% during the 2nd quarter. Jane Street Group LLC now owns 193,789 shares of the biotechnology company’s stock valued at $1,752,000 after purchasing an additional 176,876 shares during the period. Quantinno Capital Management LP lifted its holdings in shares of Grifols by 22.3% in the second quarter. Quantinno Capital Management LP now owns 118,472 shares of the biotechnology company’s stock valued at $1,071,000 after purchasing an additional 21,596 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Grifols in the third quarter worth $204,000. Finally, Franklin Resources Inc. grew its holdings in shares of Grifols by 10.9% during the fourth quarter. Franklin Resources Inc. now owns 21,343 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 2,104 shares in the last quarter.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.